[1]
S. Ols, L. Yang, E.A. Thompson, P. Pushparaj, K. Tran, F. Liang, A. Lin, B.
Eriksson, G.B. Karlsson Hedestam, R.T. Wyatt, K. Loré, Route of Vaccine
Administration Alters Antigen Trafficking but Not Innate or Adaptive Immunity,
Cell Rep. 30 (2020) 3964-3971.e7. doi:10.1016/j.celrep.2020.02.111.
[2]
D.C.C. Tang, H.H. Nguyen, The Yin-Yang arms of vaccines: Disease-fighting
power versus tissue-destructive inflammation, Expert Rev. Vaccines. 13 (2014)
417–427. doi:10.1586/14760584.2014.882775.
[3]
L. Zhang, W. Wang, S. Wang, Effect of vaccine administration modality on
immunogenicity and efficacy, Expert Rev. Vaccines. 14 (2015) 1509–1523.
doi:10.1586/14760584.2015.1081067.
[4]
C. Calzas, C. Chevalier, Innovative mucosal vaccine formulations against
influenza a virus infections, Front. Immunol. 10 (2019) 1–21.
doi:10.3389/fimmu.2019.01605.
[5]
S. Afkhami, M.R. D’Agostino, A. Zhang, H.D. Stacey, A. Marzok, A. Kang, R.
Singh, J. Bavananthasivam, G. Ye, X. Luo, F. Wang, J.C. Ang, A. Zganiacz, U.
Sankar, N. Kazhdan, J.F.E. Koenig, A. Phelps, S.F. Gameiro, S. Tang, M.
Jordana, Y. Wan, K.L. Mossman, M. Jeyanathan, A. Gillgrass, M.F.C. Medina,
F. Smaill, B.D. Lichty, M.S. Miller, Z. Xing, Respiratory mucosal delivery of
next-generation COVID-19 vaccine provides robust protection against both
ancestral and variant strains of SARS-CoV-2, Cell. 185 (2022) 896-915.e19.
46
doi:10.1016/j.cell.2022.02.005.
[6]
P.A. Kozlowski, A. Aldovini, Mucosal Vaccine Approaches for Prevention of
HIV and SIV Transmission, Curr. Immunol. Rev. 15 (2018) 102–122.
doi:10.2174/1573395514666180605092054.
[7]
E.C. Lavelle, R.W. Ward, Mucosal vaccines — fortifying the frontiers, Nat. Rev.
Immunol. 22 (2022) 236–250. doi:10.1038/s41577-021-00583-2.
[8]
A. Alu, L. Chen, H. Lei, Y. Wei, X. Tian, X. Wei, Intranasal COVID-19
vaccines: From bench to bed, EBioMedicine. 76 (2022) 103841.
doi:10.1016/j.ebiom.2022.103841.
[9]
R. Luria-Pérez, L.A. Sánchez-Vargas, P. Muñoz-López, G. Mellado-Sánchez,
Mucosal Vaccination: A Promising Alternative Against Flaviviruses, Front. Cell.
Infect. Microbiol. 12 (2022) 1–20. doi:10.3389/fcimb.2022.887729.
[10] J. Helft, F. Ginhoux, M. Bogunovic, M. Merad, Origin and functional
heterogeneity of non-lymphoid tissue dendritic cells in mice, Immunol. Rev. 234
(2010) 55–75. doi:10.1111/j.0105-2896.2009.00885.x.
[11] F. Allen, A.A. Tong, A.Y. Huang, Unique transcompartmental bridge: Antigenpresenting cells sampling across endothelial and mucosal barriers, Front.
Immunol. 7 (2016) 1–8. doi:10.3389/fimmu.2016.00231.
[12] S. Pai, V. Muruganandah, A. Kupz, What lies beneath the airway mucosal
barrier? Throwing the spotlight on antigen-presenting cell function in the lower
respiratory tract, Clin. Transl. Immunol. 9 (2020) 1–13. doi:10.1002/cti2.1158.
47
[13] R. Nowarski, R. Jackson, R.A. Flavell, The Stromal Intervention: Regulation of
Immunity and Inflammation at the Epithelial-Mesenchymal Barrier, Cell. 168
(2017) 362–375. doi:10.1016/j.cell.2016.11.040.
[14] P.J. Milpied, M.G. McHeyzer-Williams, High-affinity IgA needs TH 17 cell
functional plasticity, Nat. Immunol. 14 (2013) 313–315. doi:10.1038/ni.2567.
[15] C. Reis E Sousa, Activation of dendritic cells: Translating innate into adaptive
immunity, Curr. Opin. Immunol. 16 (2004) 21–25.
doi:10.1016/j.coi.2003.11.007.
[16] N.I. Ho, L.G.M. Huis In ’t Veld, T.K. Raaijmakers, G.J. Adema, Adjuvants
Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective
Vaccines?, Front. Immunol. 9 (2018) 2874. doi:10.3389/fimmu.2018.02874.
[17] B.J. Skidmore, J.M. Chiller, W.O. Weigle, R. Riblet, J. Watson, Immunologic
properties of bacterial lipopolysaccharide (LPS): III. Genetic linkage between the
in vitro mitogenic and in vivo adjuvant properties of LPS*, J. Exp. Med. 143
(1976) 143–150. doi:10.1084/jem.143.1.143.
[18] C.R.H. Raetz, C. Whitfield, Lipopolysaccharide endotoxins, Annu. Rev.
Biochem. 71 (2002) 635–700. doi:10.1146/annurev.biochem.71.110601.135414.
[19] B.S. Park, J.O. Lee, Recognition of lipopolysaccharide pattern by TLR4
complexes, Exp. Mol. Med. 45 (2013). doi:10.1038/emm.2013.97.
[20] T.M. Wassenaar, K. Zimmermann, Lipopolysaccharides in food, food
supplements, and probiotics: should we be worried?, Eur. J. Microbiol. Immunol.
48
8 (2018) 63–69. doi:10.1556/1886.2018.00017.
[21] J.K. Bohannon, A. Hernandez, P. Enkhbaatar, W.L. Adams, E.R. Sherwood, The
immunobiology of toll-like receptor 4 agonists: From endotoxin tolerance to
immunoadjuvants, Shock. 40 (2013) 451–462.
doi:10.1097/SHK.0000000000000042.
[22] R.S. Johnson, G.R. Her, J. Grabarek, J. Hawiger, V.N. Reinhold, Structural
characterization of monophosphoryl Lipid A homologs obtained from Salmonella
minnesota Re595 lipopolysaccharide, J. Biol. Chem. 265 (1990) 8108–8116.
doi:10.1016/s0021-9258(19)39044-1.
[23] S. Lang, X. Huang, Carbohydrate Conjugates in Vaccine Developments, Front.
Chem. 8 (2020) 1–25. doi:10.3389/fchem.2020.00284.
[24] A. Monie, C.F. Hung, R. Roden, T.C. Wu, CervarixTM:A vaccine for the
prevention of HPV 16, 18-associated cervical cancer, Biol. Targets Ther. 2
(2008) 107–113. doi:10.2147/btt.s1877.
[25] J.J. Tejada-Pérez, J.J. Vázquez-Vicente, M.R. Herrera-Burgos, F.G. MartínMartín, T. Parrón-Carreño, R. Alarcón-Rodríguez, Fendrix® vaccine
effectiveness in healthcare workers who are non-responsive to engerix b®
vaccination, Vaccines. 9 (2021) 1–9. doi:10.3390/vaccines9030279.
[26] C. Chen, C. Zhang, R. Li, Z. Wang, Y. Yuan, H. Li, Z. Fu, M. Zhou, L. Zhao,
Monophosphoryl-Lipid A (MPLA) is an efficacious adjuvant for inactivated
rabies vaccines, Viruses. 11 (2019) 1–16. doi:10.3390/v11121118.
49
[27] R. Ravindran, S. Bhowmick, A. Das, N. Ali, Comparison of BCG, MPL and
cationic liposome adjuvant systems in leishmanial antigen vaccine formulations
against murine visceral leishmaniasis, BMC Microbiol. 10 (2010).
doi:10.1186/1471-2180-10-181.
[28] T. Obata, Y. Goto, J. Kunisawa, S. Sato, M. Sakamoto, H. Setoyama, T. Matsuki,
K. Nonaka, N. Shibata, M. Gohda, Y. Kagiyama, T. Nochi, Y. Yuki, Y.
Fukuyama, A. Mukai, S. Shinzaki, K. Fujihashi, C. Sasakawa, H. Iijima, M.
Goto, Y. Umesaki, Y. Benno, H. Kiyono, Indigenous opportunistic bacteria
inhabit mammalian gut-associated lymphoid tissues and share a mucosal
antibody-mediated symbiosis, Proc. Natl. Acad. Sci. 107 (2010) 7419–7424.
doi:10.1073/pnas.1001061107.
[29] K. Hosomi, N. Shibata, A. Shimoyama, T. Uto, T. Nagatake, Y. Tojima, T.
Nishino, H. Takeyama, K. Fukase, H. Kiyono, J. Kunisawa, Lymphoid Tissue–
Resident Alcaligenes Establish an Intracellular Symbiotic Environment by
Creating a Unique Energy Shift in Dendritic Cells, Front. Microbiol. 11 (2020)
1–10. doi:10.3389/fmicb.2020.561005.
[30] N. Shibata, J. Kunisawa, K. Hosomi, Y. Fujimoto, K. Mizote, N. Kitayama, A.
Shimoyama, H. Mimuro, S. Sato, N. Kishishita, K.J. Ishii, K. Fukase, H. Kiyono,
Lymphoid tissue-resident Alcaligenes LPS induces IgA production without
excessive inflammatory responses via weak TLR4 agonist activity, Mucosal
Immunol. 11 (2018) 693–702. doi:10.1038/mi.2017.103.
50
[31] A. Shimoyama, F. Di Lorenzo, H. Yamaura, K. Mizote, A. Palmigiano, M.D.
Pither, I. Speciale, T. Uto, S. Masui, L. Sturiale, D. Garozzo, K. Hosomi, N.
Shibata, K. Kabayama, Y. Fujimoto, A. Silipo, J. Kunisawa, H. Kiyono, A.
Molinaro, K. Fukase, Lipopolysaccharide from Gut-Associated LymphoidTissue-Resident Alcaligenes faecalis: Complete Structure Determination and
Chemical Synthesis of Its Lipid A, Angew. Chemie - Int. Ed. 60 (2021) 10023–
10031. doi:10.1002/anie.202012374.
[32] A. Shimoyama, K. Fukase, Lipid A-Mediated bacterial–host chemical ecology:
Synthetic research of bacterial lipid as and their development as adjuvants,
Molecules. 26 (2021). doi:10.3390/molecules26206294.
[33] Y. Wang, K. Hosomi, A. Shimoyama, K. Yoshii, H. Yamaura, T. Nagatake, T.
Nishino, H. Kiyono, K. Fukase, J. Kunisawa, Adjuvant activity of synthetic lipid
a of alcaligenes, a gut-associated lymphoid tissue-resident commensal bacterium,
to augment antigen-specific IgG and Th17 responses in systemic vaccine,
Vaccines. 8 (2020) 1–12. doi:10.3390/vaccines8030395.
[34] K. Yoshii, K. Hosomi, A. Shimoyama, Y. Wang, H. Yamaura, T. Nagatake, H.
Suzuki, H. Lan, H. Kiyono, K. Fukase, J. Kunisawa, Chemically synthesized
alcaligenes lipid a shows a potent and safe nasal vaccine adjuvant activity for the
induction of streptococcus pneumoniae-specific IgA and Th17 mediated
protective immunity, Microorganisms. 8 (2020) 1–20.
doi:10.3390/microorganisms8081102.
51
[35] Z. Liu, K. Hosomi, A. Shimoyama, K. Yoshii, X. Sun, H. Lan, Y. Wang, H.
Yamaura, D. Kenneth, A. Saika, T. Nagatake, H. Kiyono, K. Fukase, J.
Kunisawa, Chemically Synthesized Alcaligenes Lipid A as an Adjuvant to
Augment Immune Responses to Haemophilus Influenzae Type B Conjugate
Vaccine, Front. Pharmacol. 12 (2021) 1–9. doi:10.3389/fphar.2021.763657.
[36] K. Hoshino, O. Takeuchi, T. Kawai, H. Sanjo, T. Ogawa, Y. Takeda, K. Takeda,
S. Akira, Cutting Edge: Toll-Like Receptor 4 (TLR4)-Deficient Mice Are
Hyporesponsive to Lipopolysaccharide: Evidence for TLR4 as the Lps Gene
Product. J. Immunol. 1999. 162: 3749-3752., J. Immunol. 162 (1999) 3749–3752.
[37] K.J. Ishii, C. Coban, H. Kato, K. Takahashi, Y. Torii, F. Takeshita, H. Ludwig,
G. Sutter, K. Suzuki, H. Hemmi, S. Sato, M. Yamamoto, S. Uematsu, T. Kawai,
O. Takeuchi, S. Akira, A toll-like receptor-independent antiviral response
induced by double-stranded B-form DNA, Nat. Immunol. 7 (2006) 40–48.
doi:10.1038/ni1282.
[38] T. ten Broeke, R. Wubbolts, W. Stoorvogel, MHC class II antigen presentation
by dendritic cells regulated through endosomal sorting, Cold Spring Harb.
Perspect. Biol. 5 (2013) 1–21. doi:10.1101/cshperspect.a016873.
[39] T. Nakamura, R. Moriguchi, K. Kogure, N. Shastri, H. Harashima, Efficient
MHC class I presentation by controlled intracellular trafficking of antigens in
octaarginine-modified liposomes, Mol. Ther. 16 (2008) 1507–1514.
doi:10.1038/mt.2008.122.
52
[40] K.C. Howland, L.J. Ausubel, C.A. London, A.K. Abbas, The Roles of CD28 and
CD40 Ligand in T Cell Activation and Tolerance, J. Immunol. 164 (2000) 4465–
4470. doi:10.4049/jimmunol.164.9.4465.
[41] D. Cibrián, F. Sánchez-Madrid, CD69: from activation marker to metabolic
gatekeeper, Eur. J. Immunol. 47 (2017) 946–953. doi:10.1002/eji.201646837.
[42] M.E. Martinez-Sanchez, L. Huerta, E.R. Alvarez-Buylla, C.V. Luján, Role of
cytokine combinations on CD4+ T cell differentiation, partial polarization, and
plasticity: Continuous network modeling approach, Front. Physiol. 9 (2018) 1–
14. doi:10.3389/fphys.2018.00877.
[43] S.A. Luther, J.G. Cyster, Chemokines as regulators of T cell differentiation, Nat.
Immunol. 2 (2001) 102–107. doi:10.1038/84205.
[44] L. Gu, S. Tseng, R.M. Horner, C. Tam, M. Loda, B.J. Rollins, Control of T(H) 2
polarization by the chemokine monocyte chemoattractant protein-1, Nature. 404
(2000) 407–411. doi:10.1038/35006097.
[45] J. Bystrom, T.E. Taher, M.S. Muhyaddin, F.I. Clanchy, P. Mangat, A.S. Jawad,
R.O. Williams, R.A. Mageed, Harnessing the Therapeutic Potential of Th17
Cells, Mediators Inflamm. 2015 (2015). doi:10.1155/2015/205156.
[46] C.R. Casella, T.C. Mitchell, Putting endotoxin to work for us: Monophosphoryl
lipid a as a safe and effective vaccine adjuvant, Cell. Mol. Life Sci. 65 (2008)
3231–3240. doi:10.1007/s00018-008-8228-6.
[47] H. Shen, B.M. Tesar, W.E. Walker, D.R. Goldstein, Dual Signaling of MyD88
53
and TRIF Is Critical for Maximal TLR4-Induced Dendritic Cell Maturation, J.
Immunol. 181 (2008) 1849–1858. doi:10.4049/jimmunol.181.3.1849.
[48] A.J. Lee, K.J. Cho, J.H. Kim, MyD88-BLT2-dependent cascade contributes to
LPS-induced interleukin-6 production in mouse macrophage, Exp. Mol. Med. 47
(2015) e156. doi:10.1038/emm.2015.8.
[49] R. Ahmad, A. Al-Roub, S. Kochumon, N. Akther, R. Thomas, M. Kumari, M.S.
Koshy, A. Tiss, Y.A. Hannun, J. Tuomilehto, S. Sindhu, E.D. Rosen, The
Synergy between Palmitate and TNF-α for CCL2 Production Is Dependent on the
TRIF/IRF3 Pathway: Implications for Metabolic Inflammation, J. Immunol. 200
(2018) 3599–3611. doi:10.4049/jimmunol.1701552.
[50] V. Mata-Haro, C. Cekic, M. Martin, P.M. Chilton, C.R. Casella, T.C. Mitchell,
The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of
TLR4, Science (80-. ). 316 (2007) 1628–1632. doi:10.1126/science.1138963.
[51] S. Akira, S. Uematsu, O. Takeuchi, Pathogen recognition and innate immunity,
Cell. 124 (2006) 783–801. doi:10.1016/j.cell.2006.02.015.
[52] S.A. Scarneo, A. Mansourati, L.S. Eibschutz, J. Totzke, J.R. Roques, D. Loiselle,
D. Carlson, P. Hughes, T.A.J. Haystead, Genetic and pharmacological validation
of TAK1 inhibition in macrophages as a therapeutic strategy to effectively inhibit
TNF secretion, Sci. Rep. 8 (2018) 1–11. doi:10.1038/s41598-018-35189-7.
[53] D.W. Thomson, D. Poeckel, N. Zinn, C. Rau, K. Strohmer, A.J. Wagner, A.P.
Graves, J. Perrin, M. Bantscheff, B. Duempelfeld, V. Kasparcova, J.M.
54
Ramanjulu, G.S. Pesiridis, M. Muelbaier, G. Bergamini, Discovery of GSK8612,
a Highly Selective and Potent TBK1 Inhibitor, ACS Med. Chem. Lett. 10 (2019)
780–785. doi:10.1021/acsmedchemlett.9b00027.
[54] C. Cekic, C.R. Casella, C.A. Eaves, A. Matsuzawa, H. Ichijo, T.C. Mitchell,
Selective activation of the p38 MAPK pathway by synthetic monophosphoryl
lipid A, J. Biol. Chem. 284 (2009) 31982–31991. doi:10.1074/jbc.M109.046383.
[55] C.R. Casella, T.C. Mitchell, Inefficient TLR4/MD-2 Heterotetramerization by
Monophosphoryl Lipid A, PLoS One. 8 (2013) 19–21.
doi:10.1371/journal.pone.0062622.
[56] M. Kader, M. Alaoui-EL-Azher, J. Vorhauer, B.B. Kode, J.Z. Wells, D. Stolz, G.
Michalopoulos, A. Wells, M. Scott, N. Ismail, MyD88-dependent inflammasome
activation and autophagy inhibition contributes to Ehrlichia-induced liver injury
and toxic shock, 2017. doi:10.1371/journal.ppat.1006644.
[57] J.M. Dean, X. Wang, A.M. Kaindl, P. Gressens, B. Fleiss, H. Hagberg, C.
Mallard, Microglial MyD88 signaling regulates acute neuronal toxicity of LPSstimulated microglia in vitro, Brain. Behav. Immun. 24 (2010) 776–783.
doi:10.1016/j.bbi.2009.10.018.
[58] B.S. Thompson, The low-toxicity versions of LPS, MPL(R) adjuvant and RC529,
are efficient adjuvants for CD4+ T cells, J. Leukoc. Biol. 78 (2005) 1273–1280.
doi:10.1189/jlb.0305172.
[59] W.S. Bowen, L.A. Minns, D.A. Johnson, T.C. Mitchell, M.M. Hutton, J.T.
55
Evans, Selective TRIF-dependent signaling by a synthetic toll-like receptor 4
agonist, Sci. Signal. 5 (2012) 1–11. doi:10.1126/scisignal.2001963.
[60] Y. Wang, K. Hosomi, A. Shimoyama, K. Yoshii, T. Nagatake, Y. Fujimoto, H.
Kiyono, K. Fukase, J. Kunisawa, Lipopolysaccharide Derived From the
Lymphoid-Resident Commensal Bacteria Alcaligenes faecalis Functions as an
Effective Nasal Adjuvant to Augment IgA Antibody and Th17 Cell Responses,
Front. Immunol. 12 (2021) 1–10. doi:10.3389/fimmu.2021.699349.
[61] M.T. Orr, M.S. Duthie, H.P. Windish, E.A. Lucas, J.A. Guderian, T.E. Hudson,
N. Shaverdian, J. O’Donnell, A.L. Desbien, S.G. Reed, R.N. Coler, MyD88 and
TRIF synergistic interaction is required for TH1-cell polarization with a synthetic
TLR4 agonist adjuvant, Eur. J. Immunol. 43 (2013) 2398–2408.
doi:10.1002/eji.201243124.
[62] S.N. Harbour, C.L. Maynard, C.L. Zindl, T.R. Schoeb, C.T. Weaver, Th17 cells
give rise to Th1 cells that are required for the pathogenesis of colitis, Proc. Natl.
Acad. Sci. U. S. A. 112 (2015) 7061–7066. doi:10.1073/pnas.1415675112.
[63] X. Xiao, K. Sankaranarayanan, C. Khosla, Biosynthesis and structure–activity
relationships of the lipid a family of glycolipids, Curr. Opin. Chem. Biol. 40
(2017) 127–137. doi:10.1016/j.cbpa.2017.07.008.
[64] U. Seydel, M. Oikawa, K. Fukase, S. Kusumoto, K. Brandenburg, Intrinsic
conformation of lipid A is responsible for agonistic and antagonistic activity, Eur.
J. Biochem. 267 (2000) 3032–3039. doi:10.1046/j.1432-1033.2000.01326.x.
56
[65] A.B. Schromm, K. Brandenburg, H. Loppnow, A.P. Moran, M.H.J. Koch, E.T.
Rietschel, U. Seydel, Biological activities of lipopolysaccharides are determined
by the shape of their lipid A portion, Eur. J. Biochem. 267 (2000) 2008–2013.
doi:10.1046/j.1432-1327.2000.01204.x.
[66] S.M. Zughaier, S.M. Zimmer, A. Datta, R.W. Carlson, D.S. Stephens,
Differential induction of the toll-like receptor 4-MyD88-dependent and independent signaling pathways by endotoxins, Infect. Immun. 73 (2005) 2940–
2950. doi:10.1128/IAI.73.5.2940-2950.2005.
[67] Y. Yang, J. Lv, S. Jiang, Z. Ma, D. Wang, W. Hu, C. Deng, C. Fan, S. Di, Y.
Sun, W. Yi, The emerging role of toll-like receptor 4 in myocardial
inflammation, Cell Death Dis. 7 (2016) 1–10. doi:10.1038/cddis.2016.140.
[68] E.N. Miyaji, E. Carvalho, M.L.S. Oliveira, I. Raw, P.L. Ho, Trends in adjuvant
development for vaccines: DAMPs and PAMPs as potential new adjuvants,
Brazilian J. Med. Biol. Res. 44 (2011) 500–513. doi:10.1590/S0100879X2011007500064.
[69] D. Christensen, R. Mortensen, I. Rosenkrands, J. Dietrich, P. Andersen, Vaccineinduced Th17 cells are established as resident memory cells in the lung and
promote local IgA responses, Mucosal Immunol. 10 (2017) 260–270.
doi:10.1038/mi.2016.28.
[70] A. Peck, E.D. Mellins, Precarious balance: Th17 cells in host defense, Infect.
Immun. 78 (2010) 32–38. doi:10.1128/IAI.00929-09.
57
[71] R.H.M. Raeven, D. Rockx-Brouwer, G. Kanojia, L. van der Maas, T.H.E.
Bindels, R. ten Have, E. van Riet, B. Metz, G.F.A. Kersten, Intranasal
immunization with outer membrane vesicle pertussis vaccine confers broad
protection through mucosal IgA and Th17 responses, Sci. Rep. 10 (2020) 1–11.
doi:10.1038/s41598-020-63998-2.
[72] D. Christensen, C. Polacek, D.J. Sheward, L. Hanke, A. Moliner-Morro, G.
McInerney, B. Murrell, K.T. Hartmann, H.E. Jensen, G. Jungersen, K. Illigen,
L.K. Isling, R.F. Jensen, J.S. Hansen, I. Rosenkrands, C. Fernandez-Antunez, S.
Ramirez, F. Follmann, J. Bukh, G.K. Pedersen, Protection against SARS-CoV-2
transmission by a parenteral prime—Intranasal boost vaccine strategy,
EBioMedicine. 84 (2022) 104248. doi:10.1016/j.ebiom.2022.104248.
[73] N. V Serbina, W. Kuziel, R. Flavell, S. Akira, B. Rollins, E.G. Pamer, N. Haven,
Sequential MyD88-Independent and -Dependent Activation of Innate Immune
Responses to Intracellular Bacterial Infection University of Texas at Austin,
Infection. 19 (2003) 891–901.
[74] T.H. Leung, A. Hoffmann, D. Baltimore, One Nucleotide in a κB Site Can
Determine Cofactor Specificity for NF-κB Dimers, Cell. 118 (2004) 453–464.
https://doi.org/10.1016/j.cell.2004.08.007.
[75] S. Ogawa, J. Lozach, C. Benner, G. Pascual, R.K. Tangirala, S. Westin, A.
Hoffmann, S. Subramaniam, M. David, M.G. Rosenfeld, C.K. Glass, Molecular
determinants of crosstalk between nuclear receptors and toll-like receptors, Cell.
58
122 (2005) 707–721. doi:10.1016/j.cell.2005.06.029.
[76] J. Jin, Y. Xiao, J.H. Chang, J. Yu, H. Hu, R. Starr, G.C. Brittain, M. Chang, X.
Cheng, S.C. Sun, The kinase TBK1 controls IgA class switching by negatively
regulating noncanonical NF-κB signaling, Nat. Immunol. 13 (2012) 1101–1109.
doi:10.1038/ni.2423.
[77] C. Wang, T. Chen, J. Zhang, M. Yang, N. Li, X. Xu, X. Cao, The E3 ubiquitin
ligase Nrdp1 “preferentially” promotes TLR-mediated production of type I
interferon, Nat. Immunol. 10 (2009) 744–752. doi:10.1038/ni.1742.
[78] S. Kumar, Y. Jeong, M.U. Ashraf, Y.S. Bae, Dendritic cell-mediated th2
immunity and immune disorders, Int. J. Mol. Sci. 20 (2019).
doi:10.3390/ijms20092159.
[79] M. Dalod, R. Chelbi, B. Malissen, T. Lawrence, Dendritic cell maturation:
Functional specialization through signaling specificity and transcriptional
programming, EMBO J. 33 (2014) 1104–1116. doi:10.1002/embj.201488027.
[80] A. Schlitzer, F. Ginhoux, Organization of the mouse and human DC network,
Curr. Opin. Immunol. 26 (2014) 90–99. doi:10.1016/j.coi.2013.11.002.
[81] J.K. Krishnaswamy, U. Gowthaman, B. Zhang, J. Mattsson, L. Szeponik, D. Liu,
R. Wu, T. White, S. Calabro, L. Xu, M.A. Collet, M. Yurieva, S. Alsén, P.
Fogelstrand, A. Walter, W.R. Heath, S.N. Mueller, U. Yrlid, A. Williams, S.C.
Eisenbarth, Migratory CD11b+ conventional dendritic cells induce T follicular
helper cell–dependent antibody responses, Sci. Immunol. 2 (2017) 1–14.
59
doi:10.1126/sciimmunol.aam9169.
[82] G. Izumi, H. Nakano, K. Nakano, G.S. Whitehead, S.A. Grimm, M.B. Fessler,
P.W. Karmaus, D.N. Cook, CD11b+ lung dendritic cells at different stages of
maturation induce Th17 or Th2 differentiation, Nat. Commun. 12 (2021) 1–16.
doi:10.1038/s41467-021-25307-x.
[83] N. Bles, M. Horckmans, A. Lefort, F. Libert, P. Macours, H. El Housni, F.
Marteau, J.-M. Boeynaems, D. Communi, Gene Expression Profiling Defines
ATP as a Key Regulator of Human Dendritic Cell Functions, J. Immunol. 179
(2007) 3550–3558. doi:10.4049/jimmunol.179.6.3550.
[84] T.W.K. Broughton, M.A. ElTanbouly, E. Schaafsma, J. Deng, A. Sarde, W.
Croteau, J. Li, E.C. Nowak, R. Mabaera, N.C. Smits, A. Kuta, R.J. Noelle, J.L.
Lines, Defining the Signature of VISTA on Myeloid Cell Chemokine
Responsiveness, Front. Immunol. 10 (2019) 1–13.
doi:10.3389/fimmu.2019.02641.
[85] W. Guo, S. Imai, J. Le Yang, S. Zou, M. Watanabe, Y.X. Chu, Z. Mohammad, H.
Xu, K.D. Moudgil, F. Wei, R. Dubner, K. Ren, In vivo immune interactions of
multipotent stromal cells underlie their long-lasting pain-relieving effect, Sci.
Rep. 7 (2017) 1–2. doi:10.1038/s41598-017-10251-y.
[86] J. Yang, M. Agarwal, S. Ling, S. Teitz-Tennenbaum, R.L. Zemans, J.J.
Osterholzer, T.H. Sisson, K.K. Kim, Diverse injury pathways induce alveolar
epithelial cell CCL2/12, which promotes lung fibrosis, Am. J. Respir. Cell Mol.
60
Biol. 62 (2020) 622–632. doi:10.1165/RCMB.2019-0297OC.
[87] M. Emi-Sugie, H. Saito, K. Matsumoto, Cultured human mast cells release
various chemokines after stimulation with IL-33, Allergol. Int. 70 (2021) 386–
388. doi:10.1016/j.alit.2020.12.002.
61
...
論文の公開元へ
